Compare Abbott India with Jubilant Pharmova - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs JUBILANT PHARMOVA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA JUBILANT PHARMOVA ABBOTT INDIA/
JUBILANT PHARMOVA
 
P/E (TTM) x 48.6 14.2 342.0% View Chart
P/BV x 15.7 2.7 591.7% View Chart
Dividend Yield % 0.4 0.6 78.0%  

Financials

 ABBOTT INDIA   JUBILANT PHARMOVA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
JUBILANT PHARMOVA
Mar-19
ABBOTT INDIA/
JUBILANT PHARMOVA
5-Yr Chart
Click to enlarge
High Rs8,834898 983.8%   
Low Rs5,458618 883.8%   
Sales per share (Unadj.) Rs1,731.1572.0 302.6%  
Earnings per share (Unadj.) Rs211.936.2 585.0%  
Cash flow per share (Unadj.) Rs219.959.5 369.5%  
Dividends per share (Unadj.) Rs65.004.50 1,444.4%  
Dividend yield (eoy) %0.90.6 153.2%  
Book value per share (Unadj.) Rs945.2301.9 313.1%  
Shares outstanding (eoy) m21.25159.28 13.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.11.3 311.6%   
Avg P/E ratio x33.720.9 161.2%  
P/CF ratio (eoy) x32.512.7 255.2%  
Price / Book Value ratio x7.62.5 301.2%  
Dividend payout %30.712.4 246.9%   
Avg Mkt Cap Rs m151,848120,694 125.8%   
No. of employees `0003.52.4 145.8%   
Total wages/salary Rs m4,35619,260 22.6%   
Avg. sales/employee Rs Th10,555.538,120.6 27.7%   
Avg. wages/employee Rs Th1,249.98,058.4 15.5%   
Avg. net profit/employee Rs Th1,292.22,414.3 53.5%   
INCOME DATA
Net Sales Rs m36,78691,108 40.4%  
Other income Rs m1,133357 317.0%   
Total revenues Rs m37,91991,466 41.5%   
Gross profit Rs m6,04717,390 34.8%  
Depreciation Rs m1693,709 4.6%   
Interest Rs m232,198 1.0%   
Profit before tax Rs m6,98911,840 59.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m2,4853,268 76.0%   
Profit after tax Rs m4,5035,770 78.0%  
Gross profit margin %16.419.1 86.1%  
Effective tax rate %35.627.6 128.8%   
Net profit margin %12.26.3 193.3%  
BALANCE SHEET DATA
Current assets Rs m27,61045,848 60.2%   
Current liabilities Rs m8,56920,897 41.0%   
Net working cap to sales %51.827.4 189.0%  
Current ratio x3.22.2 146.9%  
Inventory Days Days6057 106.0%  
Debtors Days Days2751 53.8%  
Net fixed assets Rs m1,05765,498 1.6%   
Share capital Rs m213159 133.4%   
"Free" reserves Rs m19,87347,930 41.5%   
Net worth Rs m20,08648,089 41.8%   
Long term debt Rs m042,429 0.0%   
Total assets Rs m29,409114,685 25.6%  
Interest coverage x311.66.4 4,878.9%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x1.30.8 157.5%   
Return on assets %15.46.9 221.5%  
Return on equity %22.412.0 186.9%  
Return on capital %34.912.4 281.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36912,422 3.0%   
Fx outflow Rs m4,91817,227 28.6%   
Net fx Rs m-4,549-4,805 94.7%   
CASH FLOW
From Operations Rs m4,99111,215 44.5%  
From Investments Rs m-2,570-10,118 25.4%  
From Financial Activity Rs m-1,4286,574 -21.7%  
Net Cashflow Rs m9937,612 13.0%  

Share Holding

Indian Promoters % 0.0 45.6 -  
Foreign collaborators % 75.0 3.5 2,142.9%  
Indian inst/Mut Fund % 7.9 8.7 90.8%  
FIIs % 0.1 21.2 0.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 21.1 81.0%  
Shareholders   18,270 23,815 76.7%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   NATCO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  GSK PHARMA  STRIDES PHARMA SCIENCE  

Compare ABBOTT INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Apr 20, 2021 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS